Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector.
Breaking News
Subscribe to VCpost newsletter
Most Popular
- Doctors Raise Concerns Over Proposed Capital Gains Tax Changes
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- IBM Set to Acquire HashiCorp in Possible Mega-Deal, Stock Skyrockets 24% to $6.1 Billion Valuation
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Student Loan Forgiveness Processing for This Group of Borrowers Will Stop Next Week
- Samsung to Implement Six-Day Work Week for Executives Slammed by Critics 'Not Effective'
- Oracle CEO Reveals Plans to Relocate World Headquarters to Nashville, Citing the City’s Reputation as Well-Established Health Center
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
